https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/accounting-profit https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/accruals https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/acquisitionrelated-costs-recognised-as-expense-for-transaction-recognised-separately-from-acquisition-of-assets-and-assumption-of-liabilities-in-business-combination https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/acquisitions-through-business-combinations-property-plant-and-equipment https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/actuarial-assumption-of-discount-rates https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/actuarial-assumption-of-expected-rates-of-salary-increases https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/actuarial-gains-losses-arising-from-changes-in-financial-assumptions-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/additional-provisions-other-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjusted-weighted-average-shares https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-decrease-increase-in-inventories https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-decrease-increase-in-other-current-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-decrease-increase-in-trade-and-other-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-depreciation-and-amortisation-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-finance-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-gain-loss-on-disposals-property-plant-and-equipment https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-gains-losses-on-change-in-fair-value-of-derivatives https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-income-tax-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-increase-decrease-in-other-current-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-increase-decrease-in-trade-account-payable https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-increase-decrease-in-trade-and-other-payables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-interest-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-losses-gains-on-disposal-of-noncurrent-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-share-based-payments https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/adjustments-for-unrealised-foreign-exchange-losses-gains https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/advances-received-for-contracts-in-progress https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/applicable-tax-rate https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/average-foreign-exchange-rate https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/balances-with-banks https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/bank-debt-instruments-held https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/bank-overdrafts-classified-as-cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/basic-and-diluted-earnings-loss-per-share https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/basic-earnings-loss-per-share https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/borrowings https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/borrowings-interest-rate https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/capital-reserve https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-and-cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-and-cash-equivalents-if-different-from-statement-of-financial-position https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-flows-from-used-in-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-flows-from-used-in-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-flows-from-used-in-operating-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-flows-from-used-in-operations https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cash-flows-from-used-in-operations-before-changes-in-working-capital https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/changes-in-other-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/closing-foreign-exchange-rate https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/comprehensive-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/construction-in-progress https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/cover-page-shares-outstanding https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-advances-to-suppliers https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-borrowings-and-current-portion-of-noncurrent-borrowings https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-deferred-income-including-current-contract-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-derivative-financial-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-finance-lease-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-financial-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-lease-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-payables-for-purchase-of-noncurrent-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-payables-on-social-security-and-taxes-other-than-income-tax https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-prepaid-expenses https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-prepayments https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-receivables-from-taxes-other-than-income-tax https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-trade-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/current-value-added-tax-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/deferred-income-classified-as-current https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/deferred-tax-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/depreciation-and-amortisation-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/depreciation-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/depreciation-property-plant-and-equipment https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/depreciation-rightofuse-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/diluted-earnings-loss-per-share https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/dilutive-effect-of-convertible-instruments-on-number-of-ordinary-shares https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/disposals-property-plant-and-equipment https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/effect-of-exchange-rate-changes-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/equity https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/equity-and-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/expected-future-minimum-sublease-payments-receivable-under-noncancellable-subleases-classified-as-operating-lease https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/expense-from-equitysettled-share-based-payment-transactions-in-which-goods-or-services-received-did-not-qualify-for-recognition-as-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/expense-from-share-based-payment-transactions-with-employees https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/expense-relating-to-leases-of-lowvalue-assets-for-which-recognition-exemption-has-been-used https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/expense-relating-to-shortterm-leases-for-which-recognition-exemption-has-been-used https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/finance-costs https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/finance-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/finance-income-cost https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/finance-lease-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/financial-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/foreign-exchange-gain https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/foreign-exchange-loss https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/form-d-other https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/gains-losses-on-exchange-differences-on-translation-recognised-in-profit-or-loss https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/gains-on-change-in-fair-value-of-derivatives https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/general-and-administrative-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/goodwill https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/gross-lease-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/impairment-loss-recognised-in-profit-or-loss-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-from-subleasing-rightofuse-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-tax-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-tax-relating-to-components-of-oci-that-will-not-be-reclassified-to-profit-or-loss https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-tax-relating-to-remeasurements-of-defined-benefit-plans-of-other-comprehensive-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-taxes-paid-refund https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-taxes-paid-refund-classified-as-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/income-taxes-paid-refund-classified-as-operating-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-in-cash-and-cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-in-working-capital https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-appropriation-of-retained-earnings https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-conversion-of-convertible-instruments https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-effect-of-changes-in-foreign-exchange-rates-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-exercise-of-warrants-equity https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-financing-cash-flows-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-obtaining-or-losing-control-of-subsidiaries-or-other-businesses-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-other-changes-liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-other-contributions-by-owners https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-share-based-payment-transactions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-transfers-and-other-changes-equity https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/increase-decrease-through-transfers-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-costs-capitalised https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-expense-for-financial-liabilities-not-at-fair-value-through-profit-or-loss https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-expense-on-bank-loans-and-overdrafts https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-expense-on-bonds https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-expense-on-borrowings https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-expense-on-finance-leases https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-expense-on-lease-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-income-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/interest-paid-classified-as-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/inventories https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/issue-of-equity https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/issued-capital https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/key-management-personnel-compensation-postemployment-benefits https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/key-management-personnel-compensation-share-based-payment https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/key-management-personnel-compensation-shortterm-employee-benefits https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/lease-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/liabilities-arising-from-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/loans-received https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/longterm-borrowings https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/longterm-deposits https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/minimum-operating-lease-payments https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/net-deferred-tax-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/net-deferred-tax-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/net-foreign-exchange-gain https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/net-foreign-exchange-loss https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-derivative-financial-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-financial-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-lease-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/noncurrent-provisions-for-employee-benefits https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/notes-and-debentures-issued https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/number-of-other-equity-instruments-outstanding-in-share-based-payment-arrangement https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/number-of-share-options-granted-in-share-based-payment-arrangement https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/number-of-shares-issued https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/number-of-shares-issued-and-fully-paid https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/number-of-shares-outstanding https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/oci-before-tax-exchange-differences-on-translation https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/oci-before-tax-gains-losses-on-remeasurements-of-defined-benefit-plans https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/oci-net-of-tax-exchange-differences-on-translation https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/operating-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-comprehensive-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-current-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-current-financial-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-current-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-current-payables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-current-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-expense-by-nature https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-finance-cost https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-finance-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-financial-liabilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-inflows-outflows-of-cash-classified-as-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-longterm-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-noncurrent-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-noncurrent-financial-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-noncurrent-nonfinancial-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-reserves https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-shortterm-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/other-tax-effects-for-reconciliation-between-accounting-profit-and-tax-expense-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/par-value-per-share https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/payables-for-purchase-of-noncurrent-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/payables-on-social-security-and-taxes-other-than-income-tax https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/payments-of-lease-liabilities-classified-as-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-issue-of-ordinary-shares https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-issuing-other-equity-instruments https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-issuing-shares https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-other-longterm-assets-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-sales-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proceeds-from-sales-or-maturity-of-financial-instruments-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/production-supplies https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/profit-loss https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/profit-loss-before-tax https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/profit-loss-from-operating-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/property-plant-and-equipment https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/proportion-of-ownership-interest-in-subsidiary https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/purchase-of-financial-instruments-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/purchase-of-intangible-assets-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/purchase-of-other-longterm-assets-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/purchase-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/purchase-of-treasury-shares https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/raw-materials https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/raw-materials-and-consumables-used https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/reimbursement-rights-at-fair-value https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/rental-expense https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/repayments-of-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/research-and-development https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/reserve-of-exchange-differences-on-translation https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/retained-earnings https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/retained-earnings-excluding-profit-loss-for-reporting-period https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/retained-earnings-profit-loss-for-reporting-period https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/revenue https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/revenue-and-operating-income https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/revenue-from-contracts-with-customers https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/rightofuse-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/rightofuse-assets-that-do-not-meet-definition-of-investment-property https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/secured-bank-loans-received https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/share-issue-related-cost https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/share-premium https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/shortterm-deposits-classified-as-cash-equivalents https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/shortterm-restructuring-provision https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/social-security-contributions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/tax-effect-from-change-in-tax-rate https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/tax-effect-of-revenues-exempt-from-taxation-2011 https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/tax-effect-of-tax-losses https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/tax-expense-income-at-applicable-tax-rate https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/total-assets https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/trade-and-other-current-payables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/trade-and-other-current-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/trade-and-other-payables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/trade-and-other-payables-to-trade-suppliers https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/trade-and-other-receivables https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/undiscounted-finance-lease-payments-to-be-received https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/undiscounted-operating-lease-payments-to-be-received https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/undrawn-borrowing-facilities https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/unsecured-bank-loans-received https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/unused-provision-reversed-other-provisions https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/wages-and-salaries https://stock.noler.com/us/stock/phaxiam-therapeutics-s-a/weighted-average-shares